Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H13ClF2N4O2 |
| Molecular Weight | 426.803 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C2=NOC(NC(=O)CC3=C(F)C=CC=C3Cl)=C2C4=NC=NC=C4
InChI
InChIKey=OHMPXDCOVKOOAN-UHFFFAOYSA-N
InChI=1S/C21H13ClF2N4O2/c22-15-2-1-3-16(24)14(15)10-18(29)27-21-19(17-8-9-25-11-26-17)20(28-30-21)12-4-6-13(23)7-5-12/h1-9,11H,10H2,(H,27,29)
| Molecular Formula | C21H13ClF2N4O2 |
| Molecular Weight | 426.803 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 13:40:11 GMT 2025
by
admin
on
Wed Apr 02 13:40:11 GMT 2025
|
| Record UNII |
M4VHS5O48Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
897644-83-6
Created by
admin on Wed Apr 02 13:40:11 GMT 2025 , Edited by admin on Wed Apr 02 13:40:11 GMT 2025
|
PRIMARY | |||
|
11626055
Created by
admin on Wed Apr 02 13:40:11 GMT 2025 , Edited by admin on Wed Apr 02 13:40:11 GMT 2025
|
PRIMARY | |||
|
M4VHS5O48Z
Created by
admin on Wed Apr 02 13:40:11 GMT 2025 , Edited by admin on Wed Apr 02 13:40:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
5-((2-Chloro-6-fluorophenyl)acetylamino)-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001
Fig. 1) is a novel p38 MAPK inhibitor synthesized by ASKA Pharmaceutical Co. Ltd. that potently inhibits the ability of p38.ALPHA. and p38.BETA. to phosphorylate target proteins (IC50 = 10.9 and 326 nM, respectively). AKP-001 ameliorated experimental colitis induced by dextran sulfate sodium in mice and by 2,4,6-trinitrobenzene sulfonic acid in rats.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiulcer, Pyrazole; Mechanism of Action: Undefined mechanism; Highest Development Phase: Phase I for Inflammatory bowel diseases
|
